Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY: Paclitaxel + Carboplatin + Durvalumab +/- Oleclumab in TNBC
NCT03616886Phase 2Active, not recruiting
- Sponsor
- Institut Jules Bordet
- Start
- Dec 2018
- Primary completion
- May 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of oleclumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Institut Jules Bordet. Primary endpoints: Adverse Events at 7 months and Clinical Benefit Rate at 24 weeks. Started Dec 2018; status: active, not recruiting.
02
Drugs
oleclumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03616886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616886.